Silexion Stock Just Split 1-for-10. The Real Test Starts Now
Silexion Therapeutics shares fell 14 cents to $4.85 in midday Nasdaq trading Wednesday, days after a 1-for-10 reverse split took effect. The company reported a first-quarter net loss of $2.7 million and $2.4 million in cash at March 31. Silexion plans to start a Phase 2/3 trial of its pancreatic cancer drug SIL204 this quarter.